ASTRO Releases Pamphlets on Lymphoma

The American Society for Therapeutic Radiology and Oncology (ASTRO) has published two new patient information brochures to help patients with lymphoma understand their treatment options. Radiation Therapy for Non- Hodgkins Lymphoma and Radiation Therapy for Hodgkins Lymphoma to help patients and their families understand how radiation therapy works to cure cancers of the lymphatic system.



"Radiation therapy has been proven to be quite effective in the treatment of lymphomas, particularly Hodgkins," said Louis Harrison, M.D., Chair of the ASTRO Communications Committee and a radiation oncologist at Beth Israel Medical Center in New York. "I hope these brochures will help people with lymphomas better understand their treatment options so they can make the best, most informed decision on their care."



The pamphlets can be downloaded at http://www.astro.org/patient/treatment_information/.

I helped proofread the drafts for ASTRO :-)

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap